Immuno-oncology
Conference Coverage
Researchers consider R/R ALL drugs in the first-line setting
CHICAGO –
News
Ibrutinib plus obinutuzumab gets priority review in CLL/SLL
This sets the stage for
Conference Coverage
DETERRED trial: Concurrent atezolizumab, CRT shows promise in LA-NSCLC
TORONTO – Concurrent atezolizumab and chemoradiation therapy is safe and showed promising efficacy in LA-NSCLC in...
From the Journals
Epacadostat plus pembrolizumab shows promise in advanced solid tumors
Investigational drug epacadostat plus pembrolizumab demonstrated promising antitumor activity and safety in patients with advanced solid tumors....
Conference Coverage
B-cell maturation antigen targeted in myeloma trials
NEW YORK – So far,
Conference Coverage
IMpower133: Atezolizumab plus standard chemotherapy boosted survival in ES-SCLC
Adding atezolizumab to standard first-line ES-SCLC treatment significantly improved overall survival and progression-free survival in the...
From the Journals
Checkpoint inhibitor linked to antiphospholipid syndrome in melanoma patient
A melanoma patient receiving pembrolizumab was diagnosed with antiphospholipid syndrome that resolved following discontinuation of that treatment...
From the Journals
First reported case of induced resistance to tisagenlecleucel
The CAR gene was unintentionally introduced into a single leukemic B cell during T-cell manufacturing.
Latest News
Researchers share Nobel Prize for cancer immunotherapy discoveries
Dr. James P. Allison and Dr. Tasuku Honjo share the Nobel Prize for their work on preventing brakes on T cells, which led to the development of...
From the Journals
Endogenous retroviruses may unlock new immunotherapy targets
Future epigenetic drugs could activate human endogenous retroviruses (HERVs) in cancer cells to enable immunotherapy, investigators suggest.
...Conference Coverage
PACIFIC trial: Durvalumab improves both OS and PFS in stage III NSCLC
TORONTO – Updated PACIFIC trial results show that durvalumab provides first major OS, PFS advance for stage III NSCLC in decades.